The existence of botulinum toxin has been known for centuries; however, its positive effects have only been appreciated in recent decades. In 1895 Professor Emile Pierre van Ermengem of Ellezelles, Belgium, identified the bacterium Bacillus botulinus. The agent, later renamed Clostridium botulinum, was the precursor to what is now known as botulinum toxin type A (BOTOX®).
BOTOX®, which has been used to treat a variety of medical conditions for nearly 15 years, is also FDA-approved as BOTOX® Cosmetic.
Since first introduced to the medical community in 1989, as a treatment for eye muscle disorders, administering of Botulinum Toxin Type A has now become the most popular non-invasive aesthetic medical procedure performed worldwide.
Botox ®: Botox has been manufactured and studied in the US since 1985, and was officially approved by the FDA for cosmetic use in April 2002. Botox Cosmetic from Allergan uses a form of the botulinum toxin so that when it is injected into facial lines, those muscles are paralyzed, making the wrinkles invisible. Results last for three to eight months and are visible within a few days after treatment. For specific product information from Allergan, go to https://www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf.
Dysport ®: Dysport, from Medicis, has been studied in Europe since 1988, has been available for use outside the US since 1991, and was recently approved for cosmetic use in the US in May 2009. Dysport is an injection used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years. The dose of Dysport is not the same as or interchangeable with the dose of any other botulinum toxin product, e.g Botox Cosmetic. For specific product information from Medicis, go to https://www.medicis.com/products/pi/pi_dysport.pdf.
Xeomin ® from by Merz Pharmaceuticals LLC, has been available outside the US since 2005, and was introduced in the US in 2010. Xeomin was given the FDA approval in July 2011 for the treatment of cervical dystonia, blepharospasm, and glabellar lines. Now, after a 10 month injuction has concluded, Xeomin has again been launched in the US in 2013. Xeomin®, by Merz Pharmaceuticals LLC, is a competitor to the well established Botox Cosmetic® and lesser used Dysport®.
Xeomin does not contain any additives. Patients are less likely to become resistant to Xeomin because there are simply less ingredients in the solution. Some patients have developed antibodies to Botox and Dysport. (Source: https://www.botoxforum.com/articles/xeomin/75).
For more information on Cosmetic Injectables such as Botox®, Dysport® and Xeomin®, the IAPAM has created a number of informative pages, including:
….. and many many more!
DISCLOSURE OF UNLABELED USE
This webpage contains discussion of agents that are not indicated by the U.S. Food and Drug Administration. The International Association for Physicians in Aesthetic Medicine (IAPAM), Allergan, Inc., Medicis, Inc., and Merz Pharmaceuticals LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed on this webpage are those of the contributors and do not necessarily represent the views of the IAPAM, Allergan, Inc., Medicis, Inc. or Merz Pharmaceuticals LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.